Journal article
Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study
- Abstract:
-
Background Typhoid fever is a major cause of morbidity and mortality in low-income and middle-income countries. In 2017, WHO recommended the programmatic use of typhoid Vi-conjugate vaccine (TCV) in endemic settings, and Gavi, The Vaccine Alliance, has pledged support for vaccine introduction in these countries. Country-level health economic evaluations are now needed to inform decision-making.
Methods In this modelling study, we compared four strat...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Version of record, pdf, 1.1MB)
-
- Publisher copy:
- 10.1016/s1473-3099(18)30804-1
Authors
Funding
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- Lancet Infectious Diseases Journal website
- Volume:
- 19
- Issue:
- 7
- Pages:
- 728-739
- Publication date:
- 2019-05-23
- Acceptance date:
- 2018-12-14
- DOI:
- EISSN:
-
1474-4457
- ISSN:
-
1473-3099
- Pmid:
-
31130329
- Source identifiers:
-
1007368
Item Description
- Language:
- English
- Pubs id:
-
pubs:1007368
- UUID:
-
uuid:4dc14378-c3b2-40e9-a490-9ef805099596
- Local pid:
- pubs:1007368
- Deposit date:
- 2019-06-06
Terms of use
- Copyright holder:
- Bilcke et al
- Copyright date:
- 2019
- Notes:
- © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record